CellCarta Partners for Lung Cancer Testing

CellCarta and Biofidelity have expanded their global strategic partnership, granting CellCarta exclusive rights to Biofidelity's Aspyre® Lung technology. This collaboration is set to advance targeted lung cancer testing capabilities. The agreement aims to enhance diagnostic accuracy and provide more precise treatment options for lung cancer patients. By combining their expertise, the companies intend to improve patient outcomes through innovative diagnostic solutions in oncology, marking a significant step in personalized medicine.